Analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post $0.59 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $0.53 to $0.64. Supernus Pharmaceuticals reported earnings per share of $0.52 during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.5%. The company is scheduled to announce its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Supernus Pharmaceuticals will report full year earnings of $2.16 per share for the current fiscal year, with EPS estimates ranging from $2.09 to $2.24. For the next fiscal year, analysts anticipate that the firm will report earnings of $1.94 per share, with EPS estimates ranging from $1.60 to $2.15. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. The firm had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. During the same period last year, the company earned $0.57 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis.

Several brokerages have recently weighed in on SUPN. Stifel Nicolaus set a $55.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group set a $46.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 29th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $53.38.

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar acquired 7,200 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $26.39 per share, for a total transaction of $190,008.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 6.57% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Municipal Employees Retirement System of Michigan increased its holdings in Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 15,650 shares of the specialty pharmaceutical company’s stock worth $518,000 after buying an additional 330 shares in the last quarter. Bridge City Capital LLC increased its holdings in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. Bridge City Capital LLC now owns 69,000 shares of the specialty pharmaceutical company’s stock worth $2,283,000 after buying an additional 338 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Supernus Pharmaceuticals by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock worth $709,000 after buying an additional 366 shares in the last quarter. Baltimore Washington Financial Advisors Inc. increased its holdings in Supernus Pharmaceuticals by 0.9% in the 2nd quarter. Baltimore Washington Financial Advisors Inc. now owns 45,033 shares of the specialty pharmaceutical company’s stock worth $1,490,000 after buying an additional 420 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in Supernus Pharmaceuticals by 8.4% in the 2nd quarter. Diversified Trust Co now owns 6,450 shares of the specialty pharmaceutical company’s stock worth $213,000 after buying an additional 500 shares in the last quarter. Institutional investors own 99.35% of the company’s stock.

Shares of NASDAQ:SUPN traded down $0.69 on Friday, hitting $27.89. 565,022 shares of the company traded hands, compared to its average volume of 544,008. Supernus Pharmaceuticals has a 52 week low of $25.32 and a 52 week high of $51.38. The company has a quick ratio of 2.53, a current ratio of 2.72 and a debt-to-equity ratio of 0.70. The stock has a 50 day simple moving average of $28.86 and a 200-day simple moving average of $33.29. The company has a market cap of $1.48 billion, a PE ratio of 13.60, a PEG ratio of 0.99 and a beta of 1.62.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

See Also: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.